Research Programs-Gene Regulation and Functional Genomics

基因调控和功能基因组学计划（GRFGP）来自于前分子生物学计划。 肿瘤学计划（MOP），已重新命名，以反映更突出的重点。重组 反映了在癌症的分子遗传学方面发生的深刻发展，以及 更广泛的基因组学领域，因为这个赠款的最后一个竞争性更新。在董事会的共同领导下。 Jeffrey Sklar和谢尔曼韦斯曼博士（MOP的前共同领导人），GRFGP旨在促进 (1)研究与肿瘤表型相关的基因表达的机制和影响， (2)研究癌症相关的人体广泛的结构和功能特征， 基因组GRFGP的这两个方面涵盖了对促进基因表达的单个基因的研究。 癌症的发展和进展以及全基因组基因表达、染色质 结构和表征或控制肿瘤状态的调节因子。此外， 该计划所涵盖的研究包括开发更好地阐明和 分析与癌症相关的基因，基因表达和DNA的变化。最后，该方案是 对癌症的生物学过程和有关这些过程的信息的应用感兴趣， 癌症的预防、诊断和治疗。通过主要关注 作为散发性癌症的分子分析，GRFGP补充了癌症遗传学的活动 该程序负责识别和分析遗传性疾病的基因， 易患癌症这两个方案进行了重要的合作，特别是在以下领域： 技术开发。GRFGP的目标是通过共同赞助 分子病毒学和肿瘤学小组会议，主要参与干细胞每周小组 会议，每周遗传学研讨会系列的组织，试点赠款计划的机构，以刺激 以项目为导向的癌症研究，以及促进成员之间的合作 在该计划和其他癌症中心的计划。 该小组由20名独立但互动的成员组成，分属于联合国8个部门。 医学院或大学。这一组经同行审查的资金支助总额约为470万美元 每年的直接费用（费用总额750万美元），其中直接费用略低于100万美元（费用总额140万美元） 来自NCI。直接供资总额为4,79万美元（费用总额为765万美元）。在上一次赠款期间， 在此期间，该计划的成员发表了208篇与癌症相关的论文，其中5.3%是计划内的 和15.9%方案间

The Program in Gene Regulation and Functional Genomics (GRFGP) is derived from the former Molecular Oncology Program (MOP) which was renamed to reflect a more sharpened focus. The reorganization reflects the profound developments that have occurred in the molecular genetics of cancer, as well as in the broader field of genomics, since the last competitive renewal of this grant. Under the joint leadership of Dr. Jeffrey Sklar and Dr. Sherman Weissman (former co-Leader of MOP), the GRFGP is designed to promote (1) research into the mechanisms and effects of gene expression relevant to the neoplastic phenotype, and (2) the investigation of cancer-associated broad-based structural and functional features of the human genome. These two aspects of the GRFGP cover the study of individual genes that contribute to the development and progression of cancer as well as the analysis of genome-wide gene expression, chromatin structure, and regulatory factors that characterize or control the neoplastic state. Furthermore, the goals of the research encompassed by this program include the development of methods to better elucidate and analyze the changes in genes, gene expression, and DNA related to cancer. Finally, this program is interested in both the biologic processes underlying cancer and the application of information about those processes to the improved prevention, diagnosis, and treatment of cancer. By focusing predominantly on the molecular analysis of sporadic cancers, the GRFGP complements the activities of the Cancer Genetics Program, which is charged with the identification and analysis of genes responsible for hereditary predisposition to cancer. The two Programs engage in significant collaborations, particularly in the area of technology development. The goals of the GRFGP are accomplished through joint sponsorship of the Molecular Virology and Oncology group meetings, major participation in the Stem Cell weekly group meetings, organization of the weekly Genetics Seminar series, institution of Pilot Grant program to stimulate programmatically-oriented research in cancer, as well as by facilitating collaboration between members within the program and other Cancer Center programs. The GRFGP consists of 20 independent but interactive members belonging to eight departments of the Medical School or University. Total peer-reviewed funding support of this group is approximately $4.7 million direct costs annually ($7.5 million total costs), of which just under $1 million direct costs ($1.4 total costs) come from NCI. Total direct funding is $4,79 million ($7.65 million total costs). During the previous grant period, members of this program published 208 cancer-related papers, of which 5.3% were intraprogrammatic and 15.9% inter-programmatic